Amgen Pushes Obesity Drug MariTide Forward, Reports 22% Q1 Revenue Growth
Pictured: Amgen's office in Florida/iStock, JHVEPhoto Amgen released its first-quarter 2024 earnings report on Thursday, touting a 22% increase in total revenues as well as positive mid-stage results for its next-generation obesity candidate …